Ruth Kieran

Dr. Ruth Kieran

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
RKRuth Kieran
Ruth Kieran
CMCarolyn Moloney
Carolyn Moloney
SAScheryll Alken
Scheryll Alken
LCLynda Corrigan
Lynda Corrigan
DGDavid Gallagher
David Gallagher
SCSinead Cuffe
Sinead Cuffe

3 April 2024 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
RKRuth Kieran
Ruth Kieran
MHMaeve Hennessy
Maeve Hennessy
KCKate Coakley
Kate Coakley
HOHazel O’sUllivan
Hazel O’sUllivan
TCTim Cronin
Tim Cronin
SOSeamus O'Reilly
Seamus O'Reilly
A combination of improvements in patient survival, increasing treatment duration, and the development of more expensive agents has led to a doubling of per-capita spending on cancer medicines in Ireland (2008–2018). Despite this, access to new drugs is poor in comparison to other EU countries. We examine methods to optimise oncology drug spending to facilitate access to newer anticancer agents. Key targets for spending optimisation (biosimilar use, clinical trials and expanded access programs, waste reduction, avoidance of futile treatment, and altered drug scheduling) were identified through an exploratory analysis. A structured literature search was performed, with a focus on articles relevant to the Irish Healthcare system, supplemented by reports from statutory bodies. At the present time, EMA-approved agents are available once approved by the NCPE. Optimising drug costs occurs through guideline-based practice and biosimilar integration, the latter provides €80 million in cost savings annually. Access to novel therapies can occur via over 50 clinical trials and 28 currently available expanded access programmes. Additional strategies include reversion to weight-based immunotherapy dosing, potentially saving €400,000 per year in our centre alone, vial sharing, and optimisation of treatment schedules. A variety of techniques are being employed by oncologists to optimise costs and increase access to innovation for patients. Use of biosimilars, drug wastage, and prescribing at end of life should be audited as key performance indicators, which may lead to reflective practice on treatment planning. Such measures could further optimise oncology drug expenditure nationally facilitating approval of new agents.

31 January 2022 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
RKRuth Kieran
Ruth Kieran
CMCatherine Murphy
Catherine Murphy
EMEileen Maher
Eileen Maher
JBJemma Buchalter
Jemma Buchalter
SSSue Sukor
Sue Sukor
SAScheryll Alken
Scheryll Alken

9 August 2023 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
RKRuth Kieran
Ruth Kieran
TMTaylor Mitchell
Taylor Mitchell
AFAfrah Al Fazari
Afrah Al Fazari
ACAleena Chinoy
Aleena Chinoy
CMCarolyn Moloney
Carolyn Moloney
JMJohn McCaffrey
John McCaffrey
Introduction: Fluorouracil (5FU) and capecitabine are metabolised by dihydropyrimidine dehydrogenase (DPD). Up to 9% of people have low levels of a working DPD enzyme and are at risk of severe toxicity from 5FU/capecitabine. In April 2020, the EMEA recommended patients undergo prospective screening for DPD deficiency before starting treatment, and this was introduced in our hospital. Methods: We retrospectively reviewed records of all patients receiving 5FU/capecitabine in a tertiary Irish cancer centre from May 2020 to April 2021 ( n = 197), and those starting first-line treatment in May 2019–April 2020 ( n = 97). Our primary outcome was to estimate the prevalence of DPYD variant genes by prospective genotypic screening, with secondary outcomes including variant prevalence by prospective and reactive screening in patients receiving first-line treatment, and 5FU toxicity/tolerability in those with detected variants. Results: In those treated 2020–2021, cancer subtypes included colorectal ( n = 120, 61%), breast ( n = 34, 17%), and biliary/pancreatic cancers ( n = 21, 11%). Median patient age was 62 (range 25–86 years); 40% ( n = 79) of patients were screened overall, with a prospective-screening deficiency prevalence of 6.8% ( n = 3 of 44). Three patients had pathogenic DPYD-variants detected by prospective screening and tolerated treatment with 50% up-front dose reduction of 5FU, two had variants of uncertain significance detected by reactive screening. Discussion: Other Irish studies estimated prevalence at 11–12%. As the number of variants detected was small, and screening rates were incomplete, our study may have underestimated prevalence. Conclusions: Approximately 6.8% of Irish patients may carry DPD deficiencies, prospective screening is essential to reduce the risk of life-threatening toxicity in these patients.

15 November 2025 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
RKRuth Kieran
Ruth Kieran
KCKate Coakley
Kate Coakley
BMBojan Macanovic
Bojan Macanovic
CWCatherine Weadick
Catherine Weadick
RKRachel Keogh
Rachel Keogh
SOSeamus O’REilly
Seamus O’REilly

12 March 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
MCMatthew Cronin
Matthew Cronin
RKRuth Kieran
Ruth Kieran
CSClara Steele
Clara Steele
KCKatie Cooke
Katie Cooke
SOSeamus O'Reilly
Seamus O'Reilly
Background: Oncology medication costs are increasing internationally; patient attitudes towards these costs remain unclear. Methods: A three-part cross-sectional questionnaire was distributed to patients with breast cancer to determine their attitudes towards oncology medication costs and to explore potential patient-acceptable methods to reduce these costs. Results: A total of 321 patients were eligible for inclusion and 180 fully completed the questionnaire (56.1% response rate). Overall, 67.8% (N = 122/180) of patients found the costs presented in the questionnaire to be unacceptable. 92.2% (N = 166/180), 87.8% (N = 158/180) and 68.9% (N = 124/180) of participants found the costs of pembrolizumab, palbociclib and trastuzumab respectively to be unacceptable. A total of 72.8% (N = 131/180) of patients indicated that they would like to be better informed about the societal costs of their cancer treatment and 81.1% (N = 146/180) of patients believed that reducing the costs of cancer treatment to society is important. There was a statistically significant difference in patient desires to be better informed of societal drug costs between those with early-stage breast cancer and those with metastatic disease (75.8% vs. 47.4%, χ2 = 6.923, p = 0.009). Conclusions: These findings indicate that many Irish patients with breast cancer find the societal costs of oncology medications to be unacceptable, and many patients have a desire to be better informed of these costs.